Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Insulet Corp (PODD)

Insulet Corp (PODD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,550,396
  • Shares Outstanding, K 70,393
  • Annual Sales, $ 2,072 M
  • Annual Income, $ 418,300 K
  • EBIT $ 437 M
  • EBITDA $ 518 M
  • 60-Month Beta 1.39
  • Price/Sales 10.87
  • Price/Cash Flow 72.09
  • Price/Book 16.26

Options Overview Details

View History
  • Implied Volatility 38.68% ( -0.08%)
  • Historical Volatility 22.43%
  • IV Percentile 54%
  • IV Rank 42.48%
  • IV High 60.02% on 04/10/25
  • IV Low 22.92% on 08/22/25
  • Put/Call Vol Ratio 0.15
  • Today's Volume 265
  • Volume Avg (30-Day) 361
  • Put/Call OI Ratio 1.31
  • Today's Open Interest 13,519
  • Open Int (30-Day) 12,344

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.45
  • Number of Estimates 11
  • High Estimate 1.86
  • Low Estimate 1.23
  • Prior Year 1.15
  • Growth Rate Est. (year over year) +26.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
290.16 +12.45%
on 11/06/25
335.26 -2.68%
on 10/22/25
+11.76 (+3.74%)
since 10/10/25
3-Month
288.02 +13.28%
on 10/01/25
353.50 -7.70%
on 09/09/25
+21.44 (+7.03%)
since 08/11/25
52-Week
230.05 +41.83%
on 03/10/25
353.50 -7.70%
on 09/09/25
+50.58 (+18.35%)
since 11/11/24

Most Recent Stories

More News
1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

ELAN : 22.86 (+2.65%)
PRVA : 24.32 (+3.89%)
PODD : 326.28 (+1.85%)
Insulet’s (NASDAQ:PODD) Q3: Strong Sales

Insulet’s (NASDAQ:PODD) Q3: Strong Sales

PODD : 326.28 (+1.85%)
Insulet: Q3 Earnings Snapshot

Insulet: Q3 Earnings Snapshot

PODD : 326.28 (+1.85%)
Insulet Reports Third Quarter 2025 Results

Raises Full Year Revenue and Margin Guidance

PODD : 326.28 (+1.85%)
Earnings To Watch: Insulet (PODD) Reports Q3 Results Tomorrow

Earnings To Watch: Insulet (PODD) Reports Q3 Results Tomorrow

PODD : 326.28 (+1.85%)
Insulet Champions Workplace Inclusion for People with Diabetes with New Data and Tools Released for Diabetes Awareness Month

Insulet launches campaign inspired by the International Diabetes Federation’s focus on diabetes, well-being, and the workplace “The Day Diabetes Showed...

PODD : 326.28 (+1.85%)
1 Safe-and-Steady Stock to Own for Decades and 2 We Brush Off

1 Safe-and-Steady Stock to Own for Decades and 2 We Brush Off

WK : 93.31 (+4.67%)
PODD : 326.28 (+1.85%)
THS : 23.34 (-0.13%)
What to Expect From Insulet's Next Quarterly Earnings Report

Insulet will release its third-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

XLV : 150.68 (+2.31%)
$SPX : 6,846.61 (+0.21%)
PODD : 326.28 (+1.85%)
Insulet Announces Appointment of Robert L. Huffines to its Board of Directors

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced...

PODD : 326.28 (+1.85%)
Leerink Partners Keeps Their Buy Rating on Insulet (PODD)

In a report released on October 14, Mike Kratky from Leerink Partners maintained a Buy rating on Insulet, with a price target of $355.00. The company’s shares closed yesterday at $312.45.Elevate Your...

PODD : 326.28 (+1.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System...

See More

Key Turning Points

3rd Resistance Point 333.87
2nd Resistance Point 330.63
1st Resistance Point 328.45
Last Price 326.28
1st Support Level 323.03
2nd Support Level 319.79
3rd Support Level 317.61

See More

52-Week High 353.50
Last Price 326.28
Fibonacci 61.8% 306.34
Fibonacci 50% 291.77
Fibonacci 38.2% 277.21
52-Week Low 230.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar